CX3CL1 and neoplasm: It could be argued that anti‐tumor effects were restricted to the FKN‐expressing tumors, while the clinical data (Fig 1G) and treatments with recombinant FKN (Fig 2B and C) strongly suggested systemic anti‐tumor activities by circulating FKN.